KRSA (KRSA) Debt-to-Asset: Latest Data, Historical Trends & Peer Comparison
What is KRSA's (KRSA) Debt-to-Asset?
For fiscal H1'26 ended Jun 30, 2026, KRSA Debt-to-Asset was 26.59%, representing a +211.49% change year over year.
For fiscal FY'25 ended Dec 31, 2025, KRSA Debt-to-Asset was 9.01%, representing a +19.04% change year over year.
Debt-to-Asset Historical Trend for KRSA
View KRSA's annual, quarterly, and TTM Debt-to-Asset data from 2017 to 2026, including historical growth rates and trend analysis.
KRSA Quarterly Data
| Metric | FY'17Dec 31, 2017 | FY'18Dec 31, 2018 | Q1'19Mar 31, 2019 | H1'19Jun 30, 2019 | 9M'19Sep 30, 2019 | FY'19Dec 31, 2019 | Q1'20Mar 31, 2020 | H1'20Jun 30, 2020 | 9M'20Sep 30, 2020 | FY'20Dec 31, 2020 | Q1'21Mar 31, 2021 | H1'21Jun 30, 2021 | 9M'21Sep 30, 2021 | FY'21Dec 31, 2021 | Q1'22Mar 31, 2022 | H1'22Jun 30, 2022 | 9M'22Sep 30, 2022 | FY'22Dec 31, 2022 | Q1'23Mar 31, 2023 | H1'23Jun 30, 2023 | 9M'23Sep 30, 2023 | FY'23Dec 31, 2023 | Q1'24Mar 31, 2024 | H1'24Jun 30, 2024 | 9M'24Sep 30, 2024 | FY'24Dec 31, 2024 | Q1'25Mar 31, 2025 | H1'25Jun 30, 2025 | 9M'25Sep 30, 2025 | FY'25Dec 31, 2025 | Q1'26Mar 31, 2026 | H1'26Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Debt-to-Asset YoY | 256.62% -- | 241.13% -6.04% | 179.32% -- | 40.05% -- | 43.16% -- | 47.59% -80.26% | 41.77% -76.71% | 48.37% +20.79% | 42.65% -1.17% | 48.44% +1.77% | 51.55% +23.42% | 13.88% -71.31% | 16.76% -60.7% | 18.68% -61.43% | 20.40% -60.43% | 27.98% +101.6% | 34.04% +103.1% | 42.19% +125.8% | 65.74% +222.25% | 48.99% +75.12% | 15.39% -54.8% | 15.60% -63.03% | 12.68% -80.71% | 12.74% -74% | 7.87% -48.87% | 7.57% -51.45% | 10.84% -14.55% | 8.54% -32.97% | 8.42% +7.04% | 9.01% +19.04% | 20.15% +85.98% | 26.59% +211.49% |
KRSA Annual Data
| Metric | FY'17Dec 31, 2017 | FY'18Dec 31, 2018 | FY'19Dec 31, 2019 | FY'20Dec 31, 2020 | FY'21Dec 31, 2021 | FY'22Dec 31, 2022 | FY'23Dec 31, 2023 | FY'24Dec 31, 2024 | FY'25Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|
Debt-to-Asset YoY | 256.62% -- | 241.13% -6.04% | 47.59% -80.26% | 48.44% +1.77% | 18.68% -61.43% | 42.19% +125.8% | 15.60% -63.03% | 7.57% -51.45% | 9.01% +19.04% |
KRSA (KRSA) : Definition & Explanation
Debt-to-Asset is a leverage metric that shows how much financial obligation the company carries relative to assets, equity, or total capital.
It matters because debt-to-asset shapes financial risk. It can affect interest burden, refinancing pressure, and how much flexibility management has if the business hits a rough patch.
It is usually calculated from balance sheet figures such as total debt, long-term debt, total liabilities, assets, equity, or capital.
Investors usually read debt-to-asset together with cash, operating cash flow, interest expense, and debt maturity profile. A higher ratio is not automatically a problem, but it leaves less room for disappointment.
KRSA (KRSA) Debt-to-Asset vs Competitors | Chemical Pharmaceuticals Comparison
Compare KRSA's (KRSA) Debt-to-Asset with competitors. View latest market cap and Debt-to-Asset performance.
| Ticker | Company | Market Cap | Debt-to-Asset |
|---|---|---|---|
| LLY | Eli Lilly | 1.08T | 76.41% |
| JNJ | Johnson & Johnson | 651.20B | 59.07% |
| ABBV | Abbvie | 466.55B | 102.41% |
| NVS | Novartis | 267.85B | 58.04% |
| NVO | Novo Nordisk | 190.81B | 64.26% |
| BMY | Bristol-Myers Squibb | 128.36B | 79.45% |
| SNY | Sanofi | 104.75B | 43.45% |
| GSK | GSK | 103.28B | 73.89% |
| TAK | Takeda Pharmaceutical | 60.21B | 52.10% |
| TEVA | Teva Pharmaceutical | 45.71B | 80.58% |
| ONC | Beone Medicines | 40.19B | 46.74% |
| RPRX | Royalty Pharma | 33.88B | 50.49% |
| VTRS | Viatris | 19.68B | 60.45% |
| JAZZ | Jazz Pharmaceuticals | 15.83B | 62.96% |
| NBIX | Neurocrine Biosciences | 15.43B | 29.76% |
| EXEL | Exelixis | 14.49B | 24.02% |
| CORT | Corcept Therapeutics | 12.42B | 22.57% |
| MDGL | Madrigal | 12.35B | 52.15% |
| AXSM | Axsome Therapeutics | 11.22B | 87.20% |
| RDY | Dr. Reddy'S Laboratories | 10.17B | 34.33% |
| ALKS | Alkermes | 7.84B | 26.85% |
| BLTE | Belite Bio | 6.86B | 1.29% |
| RYTM | Rhythm | 6.82B | 43.77% |
| MIRM | Mirum | 6.42B | 62.66% |
| BLCO | Bausch + Lomb | 5.99B | 53.51% |
| AMRX | Amneal | 5.84B | 99.84% |
| LGND | Ligand | 5.68B | 34.82% |
| DFTX | Definium | 5.20B | 24.49% |
| AMLX | Amylyx | 4.26B | 8.23% |
| TLX | Telix | 4.25B | 64.31% |
KRSA (KRSA) Debt-to-Asset Related Metrics
Explore key financial metrics related to KRSA's (KRSA) Debt-to-Asset. Click on the links below to dive deeper into similar and complementary indicators.
About KRSA (KRSA)
KRSA
Industry
--
Established Date
--
Listing Date
--
Exchange
--
Full-time Employees
--
Fiscal Year Ends
--
Website
--
Security Type
--
Office address
--
Business
--
Introduction
--